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Atomic bomb survivors are a population suitable for studying the relationship between somatic
mutation and cancer risk because their exposure doses are relatively well known and their dose
responses in terms of cancer risk have also been thoroughly studied. An analysis has been made
of erythrocyte glycophorin A (GPA) gene mutations in 1,226 atomic bomb survivors in Hiroshima
and Nagasaki. The GPA mutation frequency (Mf) increased slightly but significantly with age at
the time of measurement and with the number of cigarettes smoked. After adjustment for the
effect of smoking, the Mf was significantly higher in males than in females and higher in
Hiroshima than in Nagasaki. All of these characteristics of the background GPA Mf were in accord
with those of solid tumor incidence obtained from an earlier epidemiological study of A-bomb sur-
vivors. Analysis of the dose effect on Mf revealed the doubling dose to be about 1.20 Sv and the
minimum dose for detection of a significant increase to be about 0.24 Sv. No significant dose
effect for difference in sex, city, or age at the time of bombing was observed. Interestingly, the
doubling dose for the GPA Mf approximated that for solid cancer incidence (1.59 Sv). And the
minimum dose for detection was not inconsistent with the data for solid cancer incidence. The
dose effect was significantly higher in those diagnosed with cancer before or after measurement
than in those without a history of cancer. These findings are consistent with the hypothesis that
somatic mutations are the main cause of excess cancer risk from radiation exposure. Environ
Health Perspect 104(Suppl 3):493-496 (1996)
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Introduction
As knowledge in the molecular biology of
cancer accumulates, the field ofcancer risk
evaluation is gaining attention. Analysis of
oncogenes and tumor suppressor genes has
demonstrated that mutations such as base
substitutions, deletions, recombinations,
and amplification of DNA are crucial for
carcinogenesis (1).
The monitoring ofsomatic mutations
in vivo can be a biological marker useful in
evaluating the cancer risk from exposure to
environmental mutagens (2). Several soma-
tic mutation assays have been established
for the glycophorin A (GPA) genes in ery-
throcytes (3,4) and for the hypoxanthine
phosphoribosyltransferase (hprt) (5,6),
HLA-A (7,8), and TcRa and P genes
(9,10) in T lymphocytes. Although these
assays do not detect or quantify variations
in genes directly involved in carcinogenesis,
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they can be considered to indirecdy reflect
them. Among these assays, the GPA and
TcR assays are characteristically different;
the GPA assay is suitable for use as a life-
long biological marker of exposure to
mutagens because it detects mutations that
accumulate mainly in long-lived bone
marrow stem cells (4,11,12), and the TcR
assay has potential value as a biological
dosimeter for those experiencing recent or
chronic radiation exposure (13,14).
Populations such as atomic bomb
(A-bomb) survivors and persons who were
administered the radioactive medical
contrast agent Thorotrast are suitable for
studying the relationship between somatic
mutations and cancer risk. Their radiation
doses are relatively well known and epi-
demiological monitoring has been extensive
(15,16). In this report, we will summarize
the results among A-bomb survivors using
the erythrocyte GPA mutation assay for
biologically substantiating estimated radia-
tion doses and epidemiologically derived
risk estimates.
Materials and Methods
Subject
Peripheral blood samples were obtained
from 713A-bomb survivors from Hiroshima
and 513 survivors from Nagasaki, includ-
ing427 age- and sex-matched controls who
were exposed distally and received less than
0.005 Gy. Doses range from 0.005 to 5.0
Sv. Ages range from 43 to 96 years with an
average age of64.5 years. Donors having
the MNheterozygous blood type were
examined for GPAmutations.
For statistical analysis, subjects were
restricted to those who had not undergone
radiotherapy or chemotherapy or blood
transfusion before mutant frequency (MO
measurement. Current cigarette-smoking
behavior was ascertained simultaneously
with blood drawing. From the Radiation
Effects Research Foundation (RERF)
tumor registry database, 81 Hiroshima A-
bomb survivors were identified who had
malignant tumors, and their diagnoses and
medical treatment were confirmed from
medical charts (17).
Erydirocyte GPAMutationAssay
GPA is one ofthe major glycophorin com-
plexes abundantly expressed on the surface
ofmature erythrocytes and is the antigenic
determinant of the MN blood type. A
pair ofmonoclonal antibodies and a flow
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cytometer can be used to detect mutant
erythrocytes lacking either the M or N
products of GPA alleles among normal ery-
throcytes from MNheterozygous people.
The flow cytometric measurement of
mutants has been described previously in
detail (3,4,18).
Four types ofmutants, NO, MO, NN
and MM, can be detected using flow
cytometry. Hemizygous NO and MO
mutant cells are caused by deactivation of
M or Nalleles of the GPA gene, respec-
tively. Homozygous NNand MMmutants
may be induced by somatic recombination
ofchromosome 4 on which the Nand M
alleles reside.
Among these four types of mutants,
we will report here the precise analysis of
hemizygous mutant frequencies (M).
The analysis used here was based on
weighted bone marrow doses (19) com-
puted as the y-ray dose plus 10 times the
neutron dose. The weighting factor will be
referred to as the relative biological effec-
tiveness (RBE) of neutrons, and weighted
doses are expressed in sieverts (Sv). The
detailed method for dose-response analysis
ofMfwill be discussed elsewhere (Kyoizumi
et al.; Radiat Res, in press).
Results and Discussion
BackgoundMutantFrequency
The background GPA Mf (data not
shown) can be characterized as follows.
The frequency of GPA-NO and -MO dele-
tion type (D-type) mutants in the control
population was significantly lower in
Nagasaki than in Hiroshima. Mfs in both
cities were significantly higher in males
than in females. The reproducibility ofthe
mutation assay suggests that interindivid-
ual variability is low. Cigarette smoking
effects GPA Mfslightly but significantly; a
current smoker's Mf is higher by approxi-
mately 0.61% per cigarette smoked daily.
With age, the Mfslightly increases (approx-
imately 0.7%/year); however, the degree of
increase is small compared with the effect
ofradiation.
These characteristics ofthe background
GPA Mfcorrespond with those of back-
ground solid-cancer incidence based on
analysis of29 years ofepidemiological data
on A-bomb survivors. For example, both
solid-tumor incidence and mortality ofA-
bomb survivors increased with advancing
age and were higher in males (15). Further-
more, mortality was higher in smokers than
in nonsmokers and higher in Hiroshima
survivors than in Nagasaki survivors (20).
The GPA Mfwas fairly stable for indi-
viduals during the 5-year study period, but
a cross-sectional analysis showed an age-
related increase ofthe Mfin persons rang-
ing from 40 to 90 years old. This may
represent a long-term accumulation of
mutations in bone marrow stem cells,
which is similar to the age-related differ-
ences in somatic Mfs also reported for
other gene loci in T cells (8,9). The induc-
tion and decay rates of in vivo mutant cells
must be taken into account when consider-
ing the magnitude of the age-dependent
increase ofmutations (21).
Dose Response of
D-typeMutantFrequency
GPA-NO and GPA-MO Mfs were signifi-
cantlycorrelated (R=0.34;p<0.001).
Figure 1 shows the dose-response curve
of the GPA D-type Mf for about 1,200
survivors using the estimated dose to bone
marrow (BM), based on the Dosimetry
System 1986 (DS86) and assuming a neu-
tron relative biological effectiveness of 10.
Figure IA shows a linear dose-response
curve, excluding outliers whose Mf and
dose were more than 400 x106 and 5 Sv,
respectively. Figure 1B shows the cubic
analysis oflog-log transformed data with-
out excluding the outliers. We used a log
transformation for both GPA Mfand BM
dose because the skewness ofboth variables
gave undulyhigh influence to a small num-
ber ofpoints at the upper extreme ofthe
distribution ofvalues, even after removing
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outliers. In addition, log transformation of
dose can equalize the effect ofdose-estima-
tion error on the dose response through-
out the range ofdoses. In both statistical
analyses, Mf increases significantly with
increase of BM dose; however, a purely
cubic model best fit these data. This
implies that the initial slope ofthe dose-
response curve on the log-log scale is 0.
On the untransformed scale (Figure IA),
the log-log cubic dose response flattens out
considerably, resembling a linear dose-
response model. Interestingly, the ratio of
the GPA Mfin persons exposed to 1 Sv to
the controls is 1.87, which is close to the
relative risk of solid-tumor incidence at
1 Sv (1.63) (15).
Although the data are not shown here,
the dose responses of the GPA-MO and
GPA-NO Mfs did not differ significantly
(p =0.41) by asymptotic Wald X2 test. No
significant effects ofsex, city, smoking, or
age at the time of exposure on the dose
response of GPA Mfwere detected. GPA
D-type Mfexhibits a significantly positive
correlation to the frequency oflympho-
cytes bearing stable-type chromosome
aberrations (number of subjects = 132,
R=0.384,p<0.001).
The doubling dose for the GPA D-type
Mfis calculated to be about 1.20 Sv using
the cubic model [95% CI, 0.95-1.56],
whereas the minimum dose for detecting a
significant increase in Mf is about 0.24 Sv
using a threshold model [95% CI,
0.045-0.51 Sv]. Interestingly, the doubling
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Figure 1. Radiation dose response of the frequency of GPA deletion type mutations. A, Linear dose-response
curve; B, cubic analysis oflog-log transformed data.
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dose ofthe GPA Mfwas also close to that
ofsolid-cancer incidence in A-bomb sur-
vivors (1.59 Sv) (15), and the minimum
detection dose for the GPA Mfwas not
inconsistent with the data for solid-cancer
risk in the low-dose groups of survivors,
i.e., the point at which the relative risk for
those exposed in the 0.200 to 0.499 Sv
range first becomes significantly higher
than 1 (22,23).
These observations ofdose response are
consistent with the hypothesis that radia-
tion-induced somatic cell mutations are the
major cause of excess cancer risks after
radiation exposure.
In this context, we analyzed the GPA
Mf of patients with cancers. Figure 2
shows among Hiroshima survivors the dose
responses of the GPA D-type Mf for 81
subjects previously or subsequently diag-
nosed with cancer and for 548 subjects
with neither malignant nor benign tumors.
Statistical analysis using the log-log cubic
model revealed that the dose effect of
D-type Mfwas significantly higher in those
diagnosed with cancer before or after mea-
surement than in those without a history
of cancer (p < 0.009). The ratio of these
dose responses is about 2.3 at 5 Sv.
Thus, a higher frequency ofmutations
may contribute to the development ofcan-
cer, or the cancer group may be more sen-
sitive to radiation. In either case, the
possibility ofdosimetry error must be con-
sidered, too. Reports in the literature of
elevated Mf in cancer-prone persons are
numerous. Highly elevated GPA Mfs have
been detected in patients with ataxia
telangiectasia (14,24), Bloom's syndrome
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Figure 2. Comparison of dose response of the frequency of GPA deletion type mutations between cancer (A) and
noncancer(B) groups. The dotted line in Bindicates the same curve shown in Aforcomparison.
(14,25-27), and Fanconi's anemia (25).
In addition, among many Thorotrast
patients who are at high risk ofdeveloping
malignant tumors and leukemia (16), the
Mf is significantly higher (13,14). Thus,
we have proposed that the GPA Mfcan be
used as a biomarker for the assessment of
cancer riskamong radiation-exposed people.
Finally, understanding the interaction
between ionizing radiation and other sus-
pected causes ofcancer is critical to human
cancer-risk assessment. The possible inter-
active effects of radiation exposure and
tobacco smoking on GPA Mfin those with
cancer versus persons without cancer
should be examined in the future. Lower
GPA Mfin females suggests the possible
effect of sex hormones on either hemopoi-
etic stem-cell proliferation rates or survival
of GPA mutant cells. Continuing somatic-
mutation studies ofthe A-bomb survivors
and clinical and epidemiological follow-up
ofsurvivors whose Mfis high may one day
darify whether the GPA mutation assay is a
suitable end point for predicting cancer risk.
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